November 2014

LGC to showcase scientific excellence at 7th EBF open meeting and 1st EBF YSS

Ampersand-backed Alliance Pharma have now acquired LGC’s Drug Development Solutions Business (“DDS”).

LGC is heading to Barcelona to deliver four presentations at the prestigious European Bioanalysis Forum (EBF)open meeting, taking place on 19 -21 November.
LGC’s presentations will showcase scientific excellence through research and results covering the topics of supercharging reagents, development of robust cortisol assays, carryover in the immunoassay laboratory and ultrasensitivity immunoassays.
Rachel Green, Head of Bioanalysis & Continuous Improvement at LGC, said: “The EBF is the key industry event for our bioanalytical service area and to have four presentations featured in the programme is credit to the fantastic scientific work the team has carried out. Our vision is science for a safer world and we look forward to sharing our expertise with industry colleagues in Barcelona”.
As well as the EBF, we are also proud to have James Price, Bioanalytical Scientist at LGC on the organising committee for the 1st EBF Young Scientist Symposium (YSS), entitled “Unleashing the Future”. The YSS is taking place on Tuesday 18 November at the same venue in Barcelona, and is aimed at early-career bioanalytical scientists looking to connect with each other and share updates and experience around the important contributions they are making to achieve scientific goals.
James Price, Bioanalytical Scientist at LGC, commented: “It has been an honour to be part of the organising committee for the 1st YSS, we have a great programme and I am looking forward to the presentations and posters from all of the contributors across different organisations. LGC is delighted to be able to underline our ongoing commitment to helping develop today’s science to create tomorrow’s innovations”
To find out more about LGC’s services talk to the team at stand C1 during the EBF Open Symposium.